India's Ranbaxy logged yet another recall, while the country's stance on patent protection keeps the industry on edge.
The JD Powers survey shows health insurance communication opportunities.
Lonnel Coats is leaving after 18 years with the company.
Hospitals are contemplating financial incentives—as in fines or less support—for patients who could have signed up for health insurance but opted not to.
The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.
Advocates say the National Institutes of Health is working with 22% less buying power than it had 11 years ago.
Queensland, Australia, researchers find the risk of high-grade cervical abnormalities fell 46% among women who had received all three doses of the HPV vaccine.
Researchers say death certificates erroneously account for only the immediate cause of death, leading to a poor accounting of deaths caused by the memory-robbing disease.
The Mario Bros. company says health and fun are the way of the future.
Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.
Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.
Italy's regulator says the companies conspired to suppress Avastin sales so Lucentis could gain market share.
The White House's proposed FY 2015 budget gives an additional 1% to the FDA.
@openFDA and its related website launched February 27.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
ProPublica says drugmakers have slashed speakers' budgets.
A study says that more opioid abusers get their medications via prescription than they do second-hand.
The UK watchdog wants to know what's behind the rare-disease drug's high price.
A study showed that side-effect fears keep asthmatics from sticking to medication regimens.
The regulator—which oversees an array of matters that include deceptive advertising and robocalls—is being nudged into this part of the medical field because of the technology involved.
Roche said an onartuzumab and Tarceva mix did not help advanced non-small cell lung cancer patients with MET-positive tumors.
The drugmaker said JAK inhibitor GSK2586184 showed no effect in Phase II and has put an ulcerative colitis test on hold.
The regulator is allowing generic makers room on the OTC contraceptive shelf.
In an analysis of post-approval data, apixaban was found to be relatively safer than other oral anticoagulants in terms of serious adverse events.
Bayer bought China-based Dihon Pharmaceutical Group, which specializes in traditional Chinese medicine consumer goods.
Ten percent of surveyed doctors told the Centers for Disease Control that reimbursement rates are not enough.
Critics say the FDA is not doing enough to ensure generics quality and that communications between industry and the regulator need to improve.
Industry associations want to see how money for review applications is spent.
The NIH says the information will help researchers find the genetic underpinnings of adult diseases.
A group called the FED up! Coalition has sent a letter to FDA Commissioner Margaret Hamburg, urging her to overturn the approval.
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
The National Association of Boards of Pharmacy says about 97% of surveyed pharmacy sites fail to comply with laws.
GoQii seeks to convert tracked calories, steps and distance into a philanthropic device.
A pilot program including mailed colon-cancer screening tests increased use of the tests among under-served patients.
The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.
The drugmaker says the voluntary measure was out of an abundance of caution.
The FDA granted Breakthrough status to the daclatasvir + asunaprevir combo for hepatitis C patients with genotype 1b.
The agency says is it time to update the onerous decades-old review process.
The regulator kicked off a $20-million generics testing project in September.
Bloomberg reports that Teva has sparked interest as a takeover target.
Adding Avastin to chemotherapy added four months of survival, data show.
The generics drugmaker named Antonio Pera to the post of chief commercial officer.
Victor Dzau's six-year term starts July 1.
The reason: Diovan.
Phase-II trials showed that LDE225 for advanced basal cell carcinoma showed a clinically significant tumor response or a partial response after six months.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The drugmaker, which makes smoking-cessation products, wants electronic cigarettes to follow the same marketing restrictions.
The drugmakers admitted no wrongdoing, but are paying the state $300,000 over an agreement not to challenge generics filings.
The Washington Post was publishing studies and press releases in its science section until criticism prompted it to stop.
A consumer survey will shape the regulator's position.
The FDA found that drugs marked L-citrulline contained drugs that treat vertigo, instead of the components that treat a rare genetic disorder.
The FDA rejected J&J's expanded indication request a third time.
Digital health startup Welltok said it had received $22.1 million in Series C funding from IBM and Qualcomm Venture's life fund portfolio.
The Healthcare Businesswomen's Association announced that three women from across the healthcare industry have been named 2014 HBA Woman of the Year.
The drugmaker's consumer business could fetch over $10 billion, according to the WSJ.
Survey questions can be uploaded as needed.
Governments have been courting industry investment, reports the Wall Street Journal.
Talk of a theoretical Actelion v. Gilead drug comparison triggered investor backlash Tuesday.
An advisory panel voted 16-9 against a label change that could give naproxen a heart-friendlier label than other NSAIDs.
The US Attorney's Office for the Southern District of New York is examining how Teva has marketed MS drug Copaxone and Parkinson's medication Azilect since 2006.
Protesters find out that the Merck they were looking for isn't the Merck they protested. The confusion is a carryover from last century.
Movable Ink reports that 65% of Q4 emails were opened on a tablet or smartphone.
Hitting a vaccination rate of 80% of girls would mean 53,000 fewer cases of cervical cancer.
Mintel finds consumers are wary about how OTC stomach medicines, like Rolaids, may affect their health.
The drugmaker may be able to settle around 3,800 cases for $100 million.
A court in India ruled biosimilar drug makers will not be able to cite the drug's name, efficacy or safety profile in its marketing.
The Cleveland Clinic finds that 75% of Americans don't worry about dying of heart disease, even though it's the country's leading killer.
The Star-Ledger reports that the company's Ethicon unit destroyed development documents about its vaginal mesh products as a matter of course. The company's West Virginia legal scuffle over the product begins Monday.
The new manufacturing site will be its first in Asia.
New York's health commissioner says its painkiller prescription database has cut painkiller doctor shopping by 75%.
The agency is reorganizing and encouraging specialization.
The national drugstore chain says it's getting out of the tobacco business.
TapTrak seeks to apply behavioral tracking to clinical trials.
A sealed complaint, reported on by the Wall Street Journal, builds on concerns that were already surrounding the now-controversial Plato study.
The drug maker is reportedly talking low rates for India's market.
Ten pharma companies will share money and biomarker research under an NIH collaboration.
A panel is meeting February 10 to discuss revoking the OTC status of some medications.
The suit stalls Eli Lilly's biosimilar version of insulin glargine.
The company is rumored to be developing an app that tracks calories burned, miles walked and other data points.
The company is reported to be cutting and moving up to 4,000 jobs.
The two will explore cancer-attacking nanobodies.
168 employees will be pink-slipped this quarter.
A survey of UK-based general practitioners shows industry websites are not a go-to source for information. Reps did not fare well, either.
The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.
Amgen 2013 revenues increased by 17% from 2012 to $18.7 billion, the company reported, but it faces headwinds in 2014 for older meds.
New research finds overlap with some forms of breast, lung, and head & neck cancers, as well as 32 recurring genetic mutations.
An appeals court says J&J does not have to pay $257.7 million.
A report indicates pharma companies do not agree on what research needs to be reported.
The drug maker is kicking in $5 million—or 20% of funding—for the research "dream team," which is part of an alliance between Stand Up and the American Cancer Society.
The previous EVP of Asia Pacific ops has been appointed president of McCann Health Americas.
A quick list of who has had to sign, courtesy of HHS. Only one of the agreements has expired.
Researchers found that a signed promise not to prescribe lowered prescriptions by around 20%.
The US agency says we've got too much data that cannot be reproduced.
The news follows company statements that China is not business friendly.
FDA found workers were manipulating test data.
Preliminary documents suggest a positive view for the under-the-tongue medication.
The companies are changing the key compound.
PMLive has documents that outline a strategy to keep intellectual property laws from relaxing in South Africa.
Johnson & Johnson's chief scientific officer says the unit provides a "more focused approach to further develop and introduce our most promising medicines."
Shingles vaccinations rose when patients received information by email or mail.